Sandbox Reserved 1619: Difference between revisions

Line 39:

Mutations in GS are also connected with AD. Over 200 of GS mutations have been linked to causing AD. These mutations target "hot spots" on the enzyme and are aggregated at the interface between PS1 and APP.The vast majority of these mutations are clustered in regions surrounding the C-terminal half of the APP TM helix and the β-strand. Mutations at these locations affect the integrity of APP recruitment and catalysis, implicating a role in the development of Aβ plaques that impair neural function.

Inhibition of GS could be a potential AD treatment, but this would require targeting only APP cleavage over other GS substrates. APP cleavage leads to products such as Aβ42 and Aβ43<ref name="Yang">PMID:28628788</ref>, which are prone to aggregation and formation of Aβ plaques. Increased peptide length ~~is thought~~ to ~~cause~~ aggregations, and many of the mutations within PS1 result in elevated ratios of Aβ42 to the shorter Aβ40<ref name="Bai">PMID:26280335</ref>. The differential binding of APP and Notch to GS provides a starting point for this differentiation but will require further follow-up studies to confirm that the structural differences observed are biologically relevant. Currently, in order to combat this complex situation, differences in binding between different substrates are being utilized to create drugs that selectively inhibit APP binding with GS, and possibly create a more ideal target for AD treatment<ref name="Zhou">PMID:30630874</ref>.

Inhibition of GS could be a potential AD treatment, but this would require targeting only APP cleavage over other GS substrates. APP cleavage leads to products such as Aβ42 and Aβ43<ref name="Yang">PMID:28628788</ref>, which are prone to aggregation and formation of Aβ plaques. Increased peptide length contributes to aggregations, and many of the mutations within PS1 result in elevated ratios of Aβ42 to the shorter Aβ40<ref name="Bai">PMID:26280335</ref>. The differential binding of APP and Notch to GS provides a starting point for this differentiation but will require further follow-up studies to confirm that the structural differences observed are biologically relevant. Currently, in order to combat this complex situation, differences in binding between different substrates are being utilized to create drugs that selectively inhibit APP binding with GS, and possibly create a more ideal target for AD treatment<ref name="Zhou">PMID:30630874</ref>.

Sandbox Reserved 1619: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

Revision as of 07:53, 21 April 2020 view source Daniel Mulawa (talk \| contribs) 77 edits No edit summary ← Older edit		Revision as of 07:59, 21 April 2020 view source Daniel Mulawa (talk \| contribs) 77 edits No edit summary Newer edit →
Line 39:		Line 39:
	Mutations in GS are also connected with AD. Over 200 of GS mutations have been linked to causing AD. These mutations target "hot spots" on the enzyme and are aggregated at the interface between PS1 and APP.The vast majority of these mutations are clustered in regions surrounding the C-terminal half of the APP TM helix and the β-strand. Mutations at these locations affect the integrity of APP recruitment and catalysis, implicating a role in the development of Aβ plaques that impair neural function.		Mutations in GS are also connected with AD. Over 200 of GS mutations have been linked to causing AD. These mutations target "hot spots" on the enzyme and are aggregated at the interface between PS1 and APP.The vast majority of these mutations are clustered in regions surrounding the C-terminal half of the APP TM helix and the β-strand. Mutations at these locations affect the integrity of APP recruitment and catalysis, implicating a role in the development of Aβ plaques that impair neural function.

	Inhibition of GS could be a potential AD treatment, but this would require targeting only APP cleavage over other GS substrates. APP cleavage leads to products such as Aβ42 and Aβ43<ref name="Yang">PMID:28628788</ref>, which are prone to aggregation and formation of Aβ plaques. Increased peptide length ~~is thought~~ to ~~cause~~ aggregations, and many of the mutations within PS1 result in elevated ratios of Aβ42 to the shorter Aβ40<ref name="Bai">PMID:26280335</ref>. The differential binding of APP and Notch to GS provides a starting point for this differentiation but will require further follow-up studies to confirm that the structural differences observed are biologically relevant. Currently, in order to combat this complex situation, differences in binding between different substrates are being utilized to create drugs that selectively inhibit APP binding with GS, and possibly create a more ideal target for AD treatment<ref name="Zhou">PMID:30630874</ref>.		Inhibition of GS could be a potential AD treatment, but this would require targeting only APP cleavage over other GS substrates. APP cleavage leads to products such as Aβ42 and Aβ43<ref name="Yang">PMID:28628788</ref>, which are prone to aggregation and formation of Aβ plaques. Increased peptide length contributes to aggregations, and many of the mutations within PS1 result in elevated ratios of Aβ42 to the shorter Aβ40<ref name="Bai">PMID:26280335</ref>. The differential binding of APP and Notch to GS provides a starting point for this differentiation but will require further follow-up studies to confirm that the structural differences observed are biologically relevant. Currently, in order to combat this complex situation, differences in binding between different substrates are being utilized to create drugs that selectively inhibit APP binding with GS, and possibly create a more ideal target for AD treatment<ref name="Zhou">PMID:30630874</ref>.